Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients

Inclusion Criteria: • Patient with a biochemically documented active acromegaly, not adequately controlled by somatostatin-analogues at conventional regimen as follow : mean 1-hour GH \> 2.5 ng/mL and elevated IGF-1 (adjusted for age and gender) * Patient with reduction of either mean fasting GH at least 50% or IGF-1 at least 25% from any medical pretreatment level * Patient currently receiving somatostatin-analogues at conventional regimen (maximum registered dose) for at least 6 months before inclusion Exclusion Criteria: * Newly diagnosed or previously medically untreated acromegalic patient * Concomitant treatment with GH-receptor antagonist * Concomitant treatment with dopamine-agonist * Symptomatic cholelithiasis or choledocolithiasis * Liver transaminases (ALT, AST) elevated, but \> 3 times upper normal limit (according to local laboratory) * Previous gamma-knife radiotherapy for treatment of acromegaly * Compression of the optic chiasm causing visual field defect * Any medical conditions contraindicated in the Summary of Product Characteristic (SPC) of all drugs Other protocol-defined inclusion/exclusion criteria may apply